IMC-R117C / Immunocore - LARVOL DELTA

Developing ImmTAC against PIWIL1, a promising novel colorectal cancer target (CIMT 2025) - P1/2 | "Other CTAs, such as PRAME and MAGEs, are not sufficiently expressed in CRC, making PIWIL1 a unique and valuable CTA target for CRC. IMC-R117C is now currently being evaluated in the clinic (NCT06840119)."

IO biomarker • Colon Cancer • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • GZMB • IFNG • MSI • PRAME

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers (clinicaltrials.gov) - P1/2 | N=600 | Recruiting | Sponsor: Immunocore Ltd

New P1/2 trial • Oncology

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers (GlobeNewswire) - "Immunocore Holdings plc...announces that the first patient has been treated in the Phase 1/2 trial of its novel ImmTAC candidate, IMC-R117C, targeting PIWIL1 in colorectal and other gastrointestinal cancers....The trial will evaluate the safety and clinical activity of IMC-R117C in HLA-A*02:01-positive patients with select advanced solid tumors. In addition to evaluating IMC-R117C as a single agent, the trial will also test combinations with standards of care."

Trial status • Colorectal Cancer • Gastrointestinal Cancer

Immunocore reports second quarter financial results and provides a business update (GlobeNewswire) - "Phase 1/2 clinical trial of brenetafusp (PRAME-A02) in multiple solid tumors: The Company plans to present clinical data for brenetafusp in late-line non-small cell lung cancer (NSCLC) in the fourth quarter of 2024; IMC-T119C: Remain on track for regulatory submission of Investigational New Drug (IND) or Clinical Trial Application (CTA) for IMC-T119C in the fourth quarter of 2024; The CTA for IMC-R117C was accepted in April 2024 by the EMA, and the Phase 1 clinical trial is expected to start in the second half of 2024."

IND • New P1 trial • P1/2 data • Colorectal Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update (Immunocore Press release) - "IMC-R117C (PIWIL1) for colorectal and other gastrointestinal cancers: The Company submitted a CTA to regulatory authorities in December 2023, and expects the trial to start in the second half of 2024."

New trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation (GlobeNewswire) - "IMC-R117C (PIWIL1) for colorectal and other gastrointestinal cancers: The Company has leveraged its proprietary peptidomic (ImmSPECT) database to validate a novel target, PIWIL1. PIWIL1 is believed to play a role in tumor progression and is expressed across a range of tumors, including colorectal which is historically insensitive to immune checkpoints, as well as gastrointestinal and pancreatic cancers....The Company submitted a CTA to regulatory authorities in December 2023, and expects the trial to start this year."

New trial • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) - "The Company continues to work on expanding the PRAME franchise, with pre-clinical work ongoing for two new PRAME ImmTAC candidates, IMC-P115C (PRAME-A02 HLE) and IMC-T119C (PRAME-A24) for solid tumors, with both on-track for investigational new drug (IND) or clinical trial application (CTA) submission in 2024; IMC-R117C (PIWIL1): The Company remains on-track to submit an IND/CTA in the fourth quarter of 2023 for IMC-R117C, an ImmTAC targeting the PIWIL1 protein for colorectal and other gastrointestinal cancers."

IND • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) - "The Company is on-track to submit an IND / CTA in the fourth quarter of 2023 for IMC-R117C, an ImmTAC targeting the PIWIL1 protein for colorectal and other gastrointestinal cancers. The Company believes this is the first PIWIL1-targeted immunotherapy in development. The Company continues to work on expanding the PRAME franchise, with pre-clinical work ongoing for two new PRAME ImmTAC candidates, IMC-P115C (PRAME-A02 HLE) and IMC-T119C (PRAME-A24) for solid tumors, with both on-track for IND/CTA submission in 2024."

IND • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Immunocore announces strategic priorities including pipeline expansion for 2023 -2024 (GlobeNewswire) - "IMC-F106C (PRAME-A02)....In 2023, the Company plans to continue to expand the clinical trial footprint globally; enrolling additional patients in the expansion arms to understand the breadth of clinical activity across multiple tumor types. The Company expects to report initial data from the monotherapy and combination arms by the first half of 2024....The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND in Q4 2023."

IND • P1/2 data • Endometrial Cancer • Gynecologic Cancers • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor